Plant-derived compounds in clinical trials
http://www.sciencedirect.com/science/ar ... 4607004242
Od tysięcy lat człowiek pozyskiwał leki z roślin, artykuł dotyczy badań w latach 2000-2007, i uświadamia ile również w obecnych czasach zawdzięczamy roślinom z których uzyskujemy nowe związki chemiczne, nowe substancje czynne leków.
Leki wdrożone do stosowania:
Exelon, 2000 r. - subst. czynna winian rywastygminy pochodna fizostygminy znajdującej się w roślinie o nazwie bobotrutka trująca
PL
http://pl.wikipedia.org/wiki/Bobotrutka_trująca
http://pl.wikipedia.org/wiki/Fizostygmina
http://pl.wikipedia.org/wiki/Rywastygmina
EN
http://en.wikipedia.org/wiki/Calabar_bean
http://en.wikipedia.org/wiki/Physostigmine
http://en.wikipedia.org/wiki/Rivastigmine
Galanthamine HBr 2000r. - subst. czynna galantamina, pozyskana pierwotnie ze śnieżyczki przebiśnieg i narcyza.
PL
http://pl.wikipedia.org/wiki/Śnieżyczka_przebiśnieg
http://pl.wikipedia.org/wiki/Galantamina
EN
http://en.wikipedia.org/wiki/Snowdrop
http://en.wikipedia.org/wiki/Galantamine
Substancje pochodzenia roslinnego, będące w testach:
P58 (PYM-50028, Cogane™) in Phase II: It is a plant-derived compound obtained from a traditional Asian ‘tonic’ that
has been found beneficial to those with dementia. This novel non-peptide is being developed by Phytopharm for the
treatment of Parkinson's disease and AD type dementia. Cogane™ reverses the changes in area of the brain involved in
Parkinson's disease by inducing the production of neurotrophic factors. These growth factors promote the growth and
connectivity of neurones and reverse the atrophy of this area of the brain. In addition, this restores the learning and memory
ability in Alzheimer's disease models and thereby offers the potential to reverse the symptoms of Alzheimer's disease
[http://www.phytopharm.co.uk http://integrity.prous.com/].
Phenserine (Phenserine tartrate, Posiphen™) in Phase III/Phase I: It is a third generation derivative of phytostigmine
isolated from Physostigma venenosum (Leguminosae) being developed by Axonyx to treat mild-to-moderate Alzheimer's disease
(AD). It is a reversible acetylcholinestrase (AChE) inhibitor and also reduces the production of beta amyloid precursor
protein (β-APP). Because of this dual mechanism of action, Phenserine has the potential to improve memory as well as to slow
AD progression. Posiphen is an antiamyloidogenic agent in Phase I clinical trials at TorreyPines for the treatment of AD and
was recently acquired through a reverse merger with Axonyx [http://www.centerwatch.com http://integrity.prous.com/]; [11].
Bobotrutka trująca
PL
http://pl.wikipedia.org/wiki/Bobotrutka_trująca
http://pl.wikipedia.org/wiki/Fizostygmina
http://pl.wikipedia.org/wiki/Rywastygmina
EN
http://en.wikipedia.org/wiki/Calabar_bean
http://en.wikipedia.org/wiki/Physostigmine
http://en.wikipedia.org/wiki/Rivastigmine
ZT-1 (DEBIO-9902) in Phase II: It is a pro-drug of huperzine isolated from the club moss, Huperzia serrata
(Lycopodiaceae). ZT-1 was originally synthesized by Zhu and co-workers at Shanghai Institute of Material Medica. It is being
evaluated by Debiopharm for the treatment of AD. The dual mode of action of ZT-1, as a N-methyl-d-aspartate receptor
antagonist and an AChE inhibitor, positions it as a third generation anti-Alzheimer's product by improving the general
condition and cognitive functions of affected patients as well as having the potential of being a neuroprotectant [http://www.debiopharm.com/; [11].
Wroniec, rodzaj z rodziny widłakowatych
PL
http://pl.wikipedia.org/wiki/Wroniec_(roślina)
EN
http://en.wikipedia.org/wiki/Huperzia_serrata
http://en.wikipedia.org/wiki/Huperzine_A
Więcej o lekach na AD, w fazie testów:
http://www.alzforum.org/drg/drc/